WASHINGTON, April 18 (Reuters) - Cephalon Inc. (CEPH.O: Quote, Profile, Research) said on Tuesday that its proposed Sparlon drug to treat attention deficit hyperactivity disorder was not responsible for a case of a serious skin rash called Stevens Johnson Syndrome.
